Comparing Citius Pharmaceuticals (NASDAQ:CTXR) and Y-mAbs Therapeutics (NASDAQ:YMAB)

Y-mAbs Therapeutics (NASDAQ:YMAB) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Insider and Institutional Ownership

70.8% of Y-mAbs Therapeutics shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 22.5% of Y-mAbs Therapeutics shares are owned by insiders. Comparatively, 12.1% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Y-mAbs Therapeutics and Citius Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Y-mAbs Therapeutics	$84.55 million	2.94	-$21.43 million	($0.54)	-10.29
Citius Pharmaceuticals	N/A	N/A	-$39.14 million	N/A	N/A

Y-mAbs Therapeutics has higher revenue and earnings than Citius Pharmaceuticals.

Risk and Volatility

Y-mAbs Therapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.

Profitability

This table compares Y-mAbs Therapeutics and Citius Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Y-mAbs Therapeutics	-28.22%	-24.61%	-18.49%
Citius Pharmaceuticals	N/A	-51.69%	-37.60%

Analyst Recommendations

This is a summary of recent ratings and price targets for Y-mAbs Therapeutics and Citius Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Y-mAbs Therapeutics	1	0	7	2	3.00
Citius Pharmaceuticals	0	0	2	1	3.33

Y-mAbs Therapeutics currently has a consensus price target of $20.89, suggesting a potential upside of 275.97%. Citius Pharmaceuticals has a consensus price target of $54.50, suggesting a potential upside of 3,203.03%. Given Citius Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Y-mAbs Therapeutics.

Summary

Y-mAbs Therapeutics beats Citius Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.